Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
about
Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association dataThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Desensitization: Overcoming the Immunologic Barriers to TransplantationA phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.Obinutuzumab: the more the merrier?Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12.A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapyTreating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.Recent advances in therapy of chronic lymphocytic leukaemia.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.Current Treatment of Chronic Lymphocytic Leukemia.Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.Venetoclax and obinutuzumab in chronic lymphocytic leukemia.Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.Combination therapy with the type II anti-CD20 antibody obinutuzumab.Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia.Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
P2860
Q26738934-16277081-D0DD-43F1-A7B6-F373851E46DFQ30243968-468AA9EC-41FC-4384-9D32-47C24C6E9C69Q30397952-70C39DE1-19A7-48E9-B8FB-FC3865E2FD53Q33880538-A8234C31-4C50-4C40-91FB-CF9A80A94716Q36443136-B33CF43F-86E7-4789-BEA9-A0A023EA06A5Q37479342-0F1793D3-FA72-4CBD-9FCC-F50019F2B5C7Q37672472-8C8AA912-21F6-4E72-87C5-EA915D7E1377Q38759420-EDA41A69-7DE9-4EB6-92D9-90B9689A6A74Q38770131-2D9CE746-093F-450C-8DFC-3FC23CA4F856Q38783064-A6CCB61E-7838-4DD1-87A3-3DC6F4850E04Q38807514-612FFAD7-3820-4CC7-9631-2587D2DEA889Q38862525-49C6ADDC-0803-4FA2-9188-3C295BB357E7Q39018189-5E531FFF-CBB4-49FF-B289-E06445894902Q39129372-880F2313-314B-419E-B0E3-22BF2981B51BQ39217647-D4FB9BAC-281E-4FB5-8280-1A4110AF6A6EQ39420524-20130A0E-CA71-4673-A62D-8C39974AE9FEQ42348732-642D19A0-B5B7-4483-8D04-93D628424F5BQ47399742-46E79DE3-CDCF-4434-AFCB-1CBF9C236843Q47688545-37634D48-2C89-42AF-A84D-07B35D6B791BQ47898168-907FC646-BD56-4647-A5C2-F36899A595A9Q49716579-37164F4A-B9AB-44C3-B87C-DE6FDF303C2BQ50041876-A43D7257-5D51-4358-99CA-3993813A6046
P2860
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Randomized phase 2 study of ob ...... chronic lymphocytic leukemia.
@ast
Randomized phase 2 study of ob ...... chronic lymphocytic leukemia.
@en
type
label
Randomized phase 2 study of ob ...... chronic lymphocytic leukemia.
@ast
Randomized phase 2 study of ob ...... chronic lymphocytic leukemia.
@en
prefLabel
Randomized phase 2 study of ob ...... chronic lymphocytic leukemia.
@ast
Randomized phase 2 study of ob ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P1433
P1476
Randomized phase 2 study of ob ...... chronic lymphocytic leukemia.
@en
P2093
David J Carlile
Guenter Fingerle-Rowson
Jamie Hirata
Jeff P Sharman
Joseph M Flynn
Kathryn S Kolibaba
Michael Boxer
Nicola Tyson
Thomas J Kipps
P2860
P356
10.1182/BLOOD-2015-03-634394
P407
P50
P577
2015-10-15T00:00:00Z